Can a cancer vaccine prime the body to better fight liver tumors?

NCT ID NCT07726329

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether giving a personalized dendritic cell vaccine before a standard liver-directed therapy (TACE) can improve outcomes for people with advanced liver cancer that has not responded to other treatments. The vaccine is made from the patient's own immune cells and trained to recognize their tumor. The study will measure safety, tumor shrinkage, and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a dendritic cell vaccine followed by transcatheter arterial chemoembolization (TACE)
What this could lead to
If it works, this combination approach could offer a new treatment option for people with advanced liver cancer who have run out of standard options.
What could go wrong
This is a mid-stage trial with 100 participants, so results are not yet proven. The treatment involves two complex procedures and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chang-Gung Memorial Hospital

    Taoyuan, 33357, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.